The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
NXP Semiconductors (NXPI)
Consensus Price Target: $311.10 (39.4% implied return)
Spun off from Dutch electronics giant Philips in 2006, NXP Semiconductors (NASDAQ: NXPI) is a designer and manufacturer of chips used in autos, industrial manufacturing, mobile devices, and communications infrastructure.
Why Does NXPI Give Us Pause?
- Sales were flat over the last two years, indicating it’s failed to expand this cycle
- Anticipated sales growth of 15.4% for the next year implies demand will be shaky
At $223.19 per share, NXP Semiconductors trades at 13.5x forward P/E. To fully understand why you should be careful with NXPI, check out our full research report (it’s free).
Nike (NKE)
Consensus Price Target: $50.66 (25.7% implied return)
Originally selling Japanese Onitsuka Tiger sneakers as Blue Ribbon Sports, Nike (NYSE: NKE) is a global titan in athletic footwear, apparel, equipment, and accessories.
Why Is NKE Risky?
- Underwhelming constant currency revenue performance over the past two years suggests its product offering at current prices doesn’t resonate with customers
- Low free cash flow margin of 5.9% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
Nike’s stock price of $40.30 implies a valuation ratio of 23.8x forward P/E. If you’re considering NKE for your portfolio, see our FREE research report to learn more.
Zoetis (ZTS)
Consensus Price Target: $100.63 (32.9% implied return)
Originally spun off from Pfizer in 2013 as the world's largest pure-play animal health company, Zoetis (NYSE: ZTS) discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide.
Why Do We Think Twice About ZTS?
- 2.7% annual revenue growth over the last two years was slower than its healthcare peers
- Projected sales decline of 1.7% for the next 12 months points to a tough demand environment ahead
- Stagnant returns on capital show management has failed to improve the company’s business quality
Zoetis is trading at $75.73 per share, or 12.1x forward P/E. Dive into our free research report to see why there are better opportunities than ZTS.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
